Elon Musk’s reported drug use has Tesla Inc. board members facing a familiar quandary: having to decide what, if anything, to do about the chief executive subjecting directors and shareholders alike to great financial and legal risk.

The Wall Street Journal’s article describing Musk’s history of recreational drug use and ongoing consumption of ketamine is the latest in a long line of tests for a board packed with the CEO’s acolytes — several of whom agreed less than six months ago to return $735 million to settle a lawsuit alleging they had excessively compensated themselves.

Shareholders voiced dissatisfaction with the board last year over Tesla’s succession planning, and accused Musk of being distracted by his commitments to other companies. His chaotic 2022 takeover of Twitter Inc., the social media company he’s renamed X Corp., contributed to Tesla losing $672 billion in market capitalization that year.

--------
Subscribe to our YouTube channel: https://trib.al/KM4k5RA
Subscribe to Bloomberg Originals: https://trib.al/dJv9Uw8

Bloomberg Quicktake brings you global social video spanning business, technology, politics and culture. Make sense of the stories changing your business and your world.

Connect with us on…
YouTube:    / bloomberg  
Breaking News on YouTube:    / @bloombergquicktakenow